China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a research service cooperation agreement with US-headquartered Candid Therapeutics, Inc. This strategic partnership aims to accelerate the development of innovative T-cell engagers for autoimmune and inflammatory diseases.
Terms of the Agreement
Under the terms of the agreement, Candid Therapeutics will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics’ proprietary universal multispecific antibody platform, WuXiBody. In return, WuXi Biologics is eligible to receive an upfront payment, as well as development and sales milestones totaling up to USD 925 million, along with royalties.
Candid’s Strategic Goals
Candid, a clinical-stage biotech company focused on advancing T-cell engagers for autoimmune and inflammatory diseases, expects that WuXiBody will significantly empower its TCE pipeline development. This collaboration is anticipated to leverage WuXi Biologics’ expertise and technology to enhance Candid’s capabilities in developing cutting-edge therapies.-Fineline Info & Tech
Leave a Reply